Cartesian Therapeutics
RNAC
44 hedge funds and large institutions have $37.3M invested in Cartesian Therapeutics in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 19 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.11% less ownership
Funds ownership: 1.66% → 1.55% (-0.11%)
21% less funds holding
Funds holding: 56 → 44 (-12)
29% less capital invested
Capital invested by funds: $52.6M → $37.3M (-$15.3M)
44% less call options, than puts
Call options by funds: $5K | Put options by funds: $9K
53% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 19
68% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.09M |
| 2 |
Millennium Management
New York
|
+$926K |
| 3 |
Renaissance Technologies
New York
|
+$531K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$350K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.33M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$847K |
| 3 |
State Street
Boston,
Massachusetts
|
-$679K |
| 4 |
JP Morgan Chase
New York
|
-$606K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$504K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
51
American International Group
New York
| – | -$52K | -727 | Closed |
|
52
Walleye Trading
New York
| – | -$38K | -533 | Closed |
|
53
VOYA Investment Management
Atlanta,
Georgia
| – | -$29K | -401 | Closed |
|
54
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$28K | -389 | Closed |
|
|
PPA
55
Parametric Portfolio Associates
Seattle,
Washington
| – | -$24K | -341 | Closed |
|
56
Walleye Capital
New York
| – | -$24K | -333 | Closed |
|
57
New York State Common Retirement Fund
Albany,
New York
| – | -$12K | -173 | Closed |
|
58
Simplex Trading
Chicago,
Illinois
| – | -$11.2K | -165 | Closed |
|
|
AIP
59
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$2K | -34 | Closed |
|
|
FIA
60
FNY Investment Advisers
New York
| – | -$2K | -33 | Closed |
|
61
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1.16K | -17 | -94% |
|
62
UBS Group
Zurich,
Switzerland
| – | -$204 | -3 | -75% |
|
RNAC Hedge Fund Activity: Q2 2019 in Review
44 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2019, worth a combined $37.3M — down 29% from $52.6M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RNAC and 9 opened new positions — a net loss of 10 holders — while 19 trimmed existing stakes and 6 added.
The largest buyer was Fidelity Investments, adding an estimated $1.09M. The largest seller was BlackRock, cutting an estimated $2.33M.
- 44 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2019, down from 56 in Q1 2019.
- Funds reported $37.3M of Cartesian Therapeutics stock for Q2 2019, down 29% quarter-over-quarter.
- 9 funds opened new Cartesian Therapeutics positions in Q2 2019 and 19 closed out, a net change of -10 holders.
- The largest Cartesian Therapeutics buyer in Q2 2019 was Fidelity Investments, an estimated $1.09M added.
- The largest Cartesian Therapeutics seller in Q2 2019 was BlackRock, an estimated $2.33M sold.
Based on aggregated 13F filings for Q2 2019.